비엑스플랜트
BXPLANT (비엑스플랜트) is a Seoul-based CDRO and biotech scalerator founded in 2024 by former Daewoong Pharmaceutical executives, providing full-cycle clinical development, MIDD-based PK/PD modeling, regulatory affairs, and seed investment services to Korean biotech ventures, pharmaceutical companies, and medical device firms.
- Company typePrivate
- Founded2024
- HeadquartersSeoul, South Korea
- Headcount1–10
- GTM typeB2B
- OfferingServices
What 비엑스플랜트 does
BXPLANT (비엑스플랜트) is a privately held Clinical Development and Research Organization (CDRO) and biotech scalerator founded in January 2024 and headquartered in Seongdong-gu, Seoul, South Korea. The company operates as a 'Clinical Intelligence Agency' providing full-cycle new drug and medical device development services, spanning R&D strategy, preclinical support, clinical strategy and consulting, PK/PD Modeling & Simulation (MIDD), clinical trial operations, regulatory affairs, data management and biostatistics, pharmacovigilance, and commercialization/valuation strategy. Its core technical differentiator is a Model-Informed Drug Development (MIDD) platform combining PK/PD modeling, PBPK modeling, quantitative systems pharmacology (QSP), and population PK/PD analysis to predict clinical outcomes and optimize dose selection before trials start.
BXPLANT was co-founded by former Daewoong Pharmaceutical executives Minkeun Jo (Co-CEO, business strategy) and Heesun Kim (Co-CEO, clinical development), with a leadership team drawn from Korean pharma majors including Daewoong, Hanmi, Chong Kun Dang, Samsung BioLogics, and CJ. The company generates revenue through project-based professional services engagements billed per contract, with multi-year contracts targeted in the billions of KRW per engagement. A secondary revenue stream derives from its scalerator function, in which the company provides seed capital to biotech startups from a self-funded ~2 billion KRW investment pool and earns returns through portfolio growth and exits. BXPLANT is officially registered as a CRO with KoNECT (Korea National Enterprise for Clinical Trials).
The company targets four primary customer segments: biotech ventures and bio startups (primary), pharmaceutical companies, medical device companies, and academic medical centers/research hospitals. Named clients include Woojung BIO, ARKGEN BIOSCIONS, and Protium Science, alongside a 50+ partner ecosystem. BXPLANT reports surpassing 100 billion KRW in cumulative order volume and achieving break-even within approximately two years of founding, with an IPO targeted between 2026-2028 at a 20 billion KRW annual revenue threshold.
비엑스플랜트 firmographics
Firmographics- Name
- 비엑스플랜트
- Legal name
- BXPLANT Co., Ltd.
- Website
- https://bxplant.co.kr
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BXPLANT (비엑스플랜트) is a Seoul-based CDRO and biotech scalerator founded in 2024 by former Daewoong Pharmaceutical executives, providing full-cycle clinical development, MIDD-based PK/PD modeling, regulatory affairs, and seed investment services to Korean biotech ventures, pharmaceutical companies, and medical device firms.
- Ownership category
- akta.pro rank
비엑스플랜트 industry classification
Industry- Product category
- Clinical Development Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)
- akta.pro secondary industry
- Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)
Keywords
Where 비엑스플랜트 is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices1 record
Markets served
비엑스플랜트 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Revenue model
- CDRO Clinical Development Services: Full-cycle new drug development services spanning preclinical consulting, clinical strategy, regulatory affairs (RA), CMC, preclinical toxicity studies, and Phase 1-4 clinical trial execution. Services are project-based and billed per engagement.
- Clinical Strategy Consulting: R&D strategy formulation, Target Product Profile (TPP) optimization, clinical development plan (CDP) design, regulatory pathway optimization, and gap analysis for biotech ventures and pharmaceutical companies. Project-based consulting fees.
- Investment / Scalerator Business: Identifying promising biotech startups, providing seed capital alongside strategic guidance, facilitating investment attraction, and supporting scale-up through fund formation and follow-up support programs. Investment returns from portfolio company growth and exits.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based engagements for biotech ventures, pharmaceutical companies, and medical device companies |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
비엑스플랜트 product offering
Product offeringCore offering
BXPLANT is a CDRO (Clinical Development and Research Organization) and biotech scalerator that delivers full-cycle new drug and medical device development services spanning R&D strategy, preclinical-to-clinical translation via MIDD/PK-PD modeling, clinical trial design and operations, regulatory affairs, and commercialization/out-licensing support. The company also operates a scalerator model, providing seed capital and growth acceleration to promising biotech startups alongside its consulting and CRO services.
Product overview
BXPLANT operates as a Clinical Intelligence Agency and CDRO (Clinical Development and Research Organization) company providing a unified platform of consulting and clinical services spanning the full new drug and medical device development lifecycle. The portfolio is organized into four core service pillars — Development & Strategic Solutions (non-clinical R&D support, PK/PD Modeling & Simulation, Clinical Strategy & Consulting, and CPL Services), Clinical Research Services (Medical Affair & Writing, Clinical Operations, Data Management & Biostatistics, and Pharmacovigilance), Regulatory Affairs, and Commercialization & Valuation Strategy — complemented by six specialized expertise areas: Chemical Drugs & Biologics, Advanced Therapy Products (ATMP), Medical Devices, In Vitro Diagnostics, Post-Market Surveillance & Pharmacovigilance, and Clinical Performance & Evaluation. The company also functions as a Scalerator, identifying and accelerating promising bio healthcare startups through investment, open innovation, and growth support. Revenue is derived from consulting services and CRO contract execution, with the company targeting IPO between 2026-2028.
Differentiator
Problem solved
Functional benefit
Products and services
- Development & Strategic Solutions Tailored R&D portfolio management and asset valuation service for early development and innovation, combining non-clinical R&D support, PK/PD Modeling & Simulation, clinical strategy & consulting, and Clinical Project Lead (CPL) services. Designed for biotech ventures and pharmaceutical companies seeking to optimize go/no-go decisions, dose selection, and clinical strategy from preclinical through Phase 2 POC.
- Clinical Research Services End-to-end CRO support for all-phase clinical trials covering Medical Affair & Writing, Clinical Operations, Data Management & Biostatistics (DM/STAT), and Pharmacovigilance & Post-Market Safety. Supports pharmaceuticals, biologics, medical devices, and IVDs across clinical and post-market phases with GCP compliance and audit/inspection readiness.
- Regulatory Affairs Comprehensive regulatory strategy service from IND to marketing authorization, including CTD Module authoring, global submission readiness, and lifecycle regulatory consulting. Covers conventional and expedited pathways with local and global expertise for pharmaceuticals, biologics, medical devices, and IVDs.
- Commercialization & Valuation Strategy Venture scalerating and growth acceleration service including portfolio assessment, venture discovery & investment, clinical development support, out-licensing strategy, and exit planning. Provides biotech startups with seed capital alongside strategic guidance, facilitating investment attraction, fund formation, and global expansion support.
Quantifiable outcome
- Surpassed 100 billion KRW in order volume within ~2 years of establishment (2024-2026)
- +3 more outcomes
Companies that use 비엑스플랜트
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
비엑스플랜트 technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
비엑스플랜트 partnerships and signals
Strategic signalPartnerships
51 partnerships are on record, tiered core, strategic and minor.
- Seoul Biohub (서울바이오허브)coreBXPLANT serves as the strategic accelerator for the '2026 Seoul Biohub X SK Biopharm Open Innovation' program, leading the entire process of identifying and nurturing promising companies. BXPLANT integrates its clinical and strategic expertise to provide intensive support so that SK Biopharm and innovative startups can achieve tangible results. The program recruits startups within 8 years of establishment to leverage SK Biopharm's drug development expertise and research infrastructure.
- Kyungpook National University Hospital Clinical Trial Center (경북대학교병원 임상시험센터)coreBXPLANT and Kyungpook National University Hospital's Clinical Trial Center and Advanced Clinical Trial Center signed an MOU for strategic cooperation in clinical trial and clinical development. The partnership provides BXPLANT's CDRO-based services (clinical development strategy, trial design and operations, project management) alongside the hospital's medical staff, patient recruitment networks, and clinical infrastructure. The goal is to enable global-level clinical trial performance outside the Seoul metropolitan area and expand access for regional patients.
- KDRA - Korea Drug Development Research Association (한국신약개발연구조합)strategicBXPLANT co-hosted the 2025 Drug Development Strategy Course with KDRA's Bio Healthcare Talent Development Center. BXPLANT leadership served as instructors, providing training on clinical development strategy. KDRA and BXPLANT also offer free R&D, clinical development, and regulatory strategy consulting services for KDRA member companies.
- KDRA Bio Healthcare Talent Development Center (KDRA 바이오헬스 인재개발센터)strategicBXPLANT co-hosted the 2025 Drug Development Strategy Course with KDRA's Bio Healthcare Talent Development Center. BXPLANT leadership served as instructors, providing training on clinical development strategy. KDRA and BXPLANT also offer free R&D, clinical development, and regulatory strategy consulting services for KDRA member companies.
- Korea University Medical Research & Business Foundation (고려대학교 의료원산학협력단)coreBXPLANT and Korea University Medical Center's academic-industry collaboration foundation signed an MOU for technology commercialization. The partnership aims to discover excellent technologies, facilitate R&D planning, identify demand companies for technology transfer, provide startup consulting, and support growth consulting across the full technology commercialization cycle. KU Medical Center has been designated as a research-focused hospital across all three campuses.
- ARKGEN BIOSCIONS (아크젠바이오사이온스)strategicBXPLANT and ARKGEN BIOSCIONS signed an MOU for biopharmaceutical development collaboration. BXPLANT supports ARKGEN's biopharmaceutical development through preclinical and clinical development strategy formulation, global regulatory compliance, and clinical trial design and execution. ARKGEN focuses on multi-antibody therapeutics and cancer treatment vaccines. BXPLANT leverages its expertise to help ARKGEN pursue rapid and efficient development.
- KDRA - Korea Drug Development Research Association (한국신약개발연구조합)strategicKDRA signed an MOU with DreamCIS, MediTip, and BXPLANT for full-cycle bio healthcare new drug development support. The partnership provides joint strategic consulting across early R&D, preclinical trials, regulatory affairs, clinical trials, business development, and investment for KDRA member companies. Additionally, the parties collaborate on developing strategic training programs for global market entry.
- PCMO - Public CDMO for Microbial-based Vaccines (미생물실증지원센터)strategicBXPLANT and PCMO (a government-supported CDMO in Hwasun, Jeollanam-do established in 2017 with support from Ministry of Trade, Industry and Energy and Hwasun County) signed an MOU for full-cycle pharmaceutical development collaboration. BXPLANT combines its CDRO services with PCMO's manufacturing technology and production capabilities to accelerate Korea's bio industry and strengthen global market competitiveness. PCMO targets mRNA vaccine manufacturing facility completion in H1 2025.
- Woojung BIO (우정바이오)strategicBXPLANT and Woojung BIO (preclinical testing specialist) co-hosted a seminar series on preclinical/clinical development strategies for successful new drug development. The second session focused on 'Establishing Proper Preclinical-Clinical Strategy for IND Approval.' BXPLANT CEO Heesun Kim served as speaker alongside researchers from KRIBB and Samsung Bioepis. PK/PD expertise spanning preclinical to clinical development was shared, with Woojung BIO providing open innovation opportunities to biotech companies.
- Protium Science (프로티움사이언스)coreBXPLANT and Protium Science (a CDAO specialist and subsidiary of KOSDAQ-listed Tium Bio) signed a strategic partnership for CDMO and CDRO integration. The collaboration links CDAO & CDMO services with CDRO services, enabling integrated clinical development solutions for clients with advanced technologies. Protium Science provides biopharmaceutical production services from cell line development to API and finished drug product manufacturing, along with regulatory consulting.
- Bitrial Clinical ResearchminorBitrial Clinical Research is listed among BXPLANT's valued partner companies on the company homepage.
- Lightning HealthminorLightning Health is listed among BXPLANT's valued partner companies on the company homepage.
- ArriellominorArriello is listed among BXPLANT's valued partner companies on the company homepage.
- AlcuraminorAlcura is listed among BXPLANT's valued partner companies on the company homepage. Alcura operates in the pharmaceutical/biotech services sector.
- Korea Biotechnology Industry Organization (KoreaBIO) (한국바이오협회)strategicBXPLANT and KoreaBIO conducted a strategic member meeting and jointly organized the 'Bio Bridge' development boot camp. The collaboration focuses on supporting biotech companies with pre-clinical and clinical development strategies, providing 1:1 expert consulting and deep training on development strategy. KoreaBIO aims to leverage BXPLANT's expertise to serve as a more robust platform connecting startups with pharmaceutical companies, research institutions, and investment networks.
- Avanti (아벤티)minorAvanti is listed among BXPLANT's valued partner companies on the company homepage. Operates in the pharmaceutical/healthcare sector.
- CJ Bioscience (CJ바이오사이언스)minorCJ Bioscience is listed among BXPLANT's valued partner companies on the company homepage. CJ Bioscience is a Korean biotech company developing biosimilars and novel biologics.
- EpiBiotech (에피바이오텍)minorEpiBiotech is listed among BXPLANT's valued partner companies on the company homepage. EpiBiotech is a Korean biotech company focused on epigenetic therapeutics.
- Honeynaps ( honeynaps)minorHoneynaps is listed among BXPLANT's valued partner companies on the company homepage. Honeynaps is a Korean biotech company.
- Daiichi Sankyo (다이아치 sankyo)minorDaiichi Sankyo is listed among BXPLANT's valued partner companies on the company homepage. Daiichi Sankyo is a global pharmaceutical company.
- Prestige Biopharma (프레스티지바이오파마)minorPrestige Biopharma is listed among BXPLANT's valued partner companies on the company homepage. Prestige Biopharma is a Singapore-based biopharmaceutical company.
- Poonglim Pharm (풍림무약)minorPoonglim Pharm is listed among BXPLANT's valued partner companies on the company homepage.
- Klotho Sciences (클로토 사이언스)minorKlotho Sciences is listed among BXPLANT's valued partner companies on the company homepage.
- CureVerse (큐어버스)minorCureVerse is listed among BXPLANT's valued partner companies on the company homepage.
- Curamis (큐라미스)minorCuramis is listed among BXPLANT's valued partner companies on the company homepage.
- Kolon Life Science (코오롱생명과학)minorKolon Life Science is listed among BXPLANT's valued partner companies on the company homepage.
- Kine Sciences (카인사이언스)minorKine Sciences is listed among BXPLANT's valued partner companies on the company homepage.
- Jiufarm (지유팜)minorJiufarm is listed among BXPLANT's valued partner companies on the company homepage.
- JETEMA (제테마)minorJETEMA is listed among BXPLANT's valued partner companies on the company homepage. JETEMA is a Korean pharmaceutical company.
- ETU (이튜)minorETU is listed among BXPLANT's valued partner companies on the company homepage.
- Yuhan Health (유한건강생활)minorYuhan Health is listed among BXPLANT's valued partner companies on the company homepage.
- Yuyu Pharma (유유제약)minorYuyu Pharma is listed among BXPLANT's valued partner companies on the company homepage. Yuyu Pharma is a Korean pharmaceutical company.
- USB Global (유스바이오글로벌)minorUSB Global is listed among BXPLANT's valued partner companies on the company homepage. USB Global is a Korean biotech company.
- Ozonbio (오즈온바이오)minorOzonbio is listed among BXPLANT's valued partner companies on the company homepage.
- Entwick (entwick)minorEntwick is listed among BXPLANT's valued partner companies on the company homepage.
- Epinod (에피노드)minorEpinod is listed among BXPLANT's valued partner companies on the company homepage.
- AIRS Medical (airs-medical)minorAIRS Medical is listed among BXPLANT's valued partner companies on the company homepage. AIRS Medical is a Korean medtech company.
- Animus Cure (애니머스큐어)minorAnimus Cure is listed among BXPLANT's valued partner companies on the company homepage.
- CSG Rejon (씨케이리제온)minorCSG Rejon is listed among BXPLANT's valued partner companies on the company homepage.
- Sirnagen ( sirnagen)minorSirnagen is listed among BXPLANT's valued partner companies on the company homepage.
- Sobagen (소바젠)minorSobagen is listed among BXPLANT's valued partner companies on the company homepage.
- BTSynergy (비티시너지)minorBTSynergy is listed among BXPLANT's valued partner companies on the company homepage.
- Berum (베름)minorBerum is listed among BXPLANT's valued partner companies on the company homepage.
- Remonex (레모넥스)minorRemonex is listed among BXPLANT's valued partner companies on the company homepage.
- DKi (dki)minorDKi is listed among BXPLANT's valued partner companies on the company homepage.
- Decasight (decasight)minorDecasight is listed among BXPLANT's valued partner companies on the company homepage. Decasight is a Korean medtech company.
- Kangstem (kangstem)minorKangstem is listed among BXPLANT's valued partner companies on the company homepage. Kangstem is a Korean biotech company.
- SK Chemicals (SK-chemicals)minorSK Chemicals is listed among BXPLANT's valued partner companies on the company homepage. SK Chemicals is a Korean chemical and pharmaceutical company.
- Mazu (메쥬)minorMazu is listed among BXPLANT's valued partner companies on the company homepage.
- BR Pharma (br-pharm)minorBR Pharma is listed among BXPLANT's valued partner companies on the company homepage.
- BXPLANT (비엑스플랜트) Co-founders: Minkeun Jo and Heesun KimcoreBXPLANT was co-founded in January 2024 by former Daewoong Pharmaceutical executives Minkeun Jo (CEO, business expert with Master's in Economics and Ph.D. in Business Administration, former Business Unit Director at Daewoong Consumer Healthcare and Head of Management Planning at Woojung BIO) and Heesun Kim (CEO, new drug development expert with Master's in Pharmacy and Ph.D. in Clinical Trial Design, former Clinical Development Director at NextBio Science, Director of Clinical/Regulatory Affairs at Inventage Lab, and Head of Clinical Development Center at Daewoong Pharmaceutical). The company operates as a Science to Business platform providing total clinical development services across the full new drug development cycle.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
비엑스플랜트 competitors and assessment
Company assessmentBroad incumbents
- IQVIA: Global CRO and life sciences services leader with deep Korean operations. While IQVIA is far broader than BXPLANT, it competes for large pharma Phase 3 outsourcing and increasingly for biosimulation/MIDD work in Korea.
- Medpace: Global mid-sized CRO focused on biotech and small pharma sponsors. Medpace represents the type of full-service biotech-focused CRO that BXPLANT could either compete with for Korean biotech clients or partner with for global trial execution.
Direct peers
- MediTip: Korean CRO offering clinical operations, regulatory affairs, and pharmacovigilance. MediTip is a co-MOU partner with BXPLANT under KDRA and competes for similar biotech venture and small pharma clients in Korea.
- Certara: Global leader in biosimulation and model-informed drug development (PBPK, PK/PD, QSP). BXPLANT positions its MIDD/PK-PD platform on the same scientific stack as Certara, though BXPLANT localizes it for Korean biotech ventures. Certara is listed among BXPLANT's partners but is simultaneously a competitor for MIDD consulting work.
- DreamCIS: Korean CRO with comprehensive clinical development, biostatistics, and regulatory services. DreamCIS is a KDRA co-MOU partner with BXPLANT and competes directly for biotech venture clinical execution contracts in Korea.
- LSK Global Pharma Services: Mid-sized Korean CRO covering clinical operations, biometrics, regulatory affairs, and pharmacovigilance. LSK Global competes head-to-head with BXPLANT for biotech venture Phase 1-3 clinical trial contracts in Korea.
- C&R Research: Korean CRO with full-service clinical development and bioequivalence offerings. C&R Research provides comparable Phase 1-4 clinical services, regulatory strategy, and biostatistics to Korean biotech and pharma clients.
Emerging players
- Molecular Health: German data-driven drug development decision support firm. Molecular Health is a BXPLANT partner that offers comparable analytics-enabled clinical strategy support, positioning it as a niche competitor in data-driven R&D strategy.
- Physiomics: UK-based computational biology and systems biology services firm providing PK/PD and QSP modeling. Physiomics is listed as a BXPLANT partner but performs overlapping biosimulation work for biotech clients, making it a partial competitor in the MIDD niche.
- Simulations Plus: US-listed biosimulation software and services firm offering PBPK, QSP, and PK/PD modeling platforms. Simulations Plus is a direct competitor for MIDD-oriented consulting engagements and represents the kind of vertically integrated platform BXPLANT's MIDD strategy could eventually be benchmarked against.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
비엑스플랜트 social profiles
Digital presence비엑스플랜트 financial estimates
Financial estimateRevenue estimate
Valuation estimate
비엑스플랜트 leadership team
Management profileNumber of profiles
Profiles6 records
비엑스플랜트 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
비엑스플랜트 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 비엑스플랜트
What does 비엑스플랜트 do?
BXPLANT is a CDRO (Clinical Development and Research Organization) and biotech scalerator that delivers full-cycle new drug and medical device development services spanning R&D strategy, preclinical-to-clinical translation via MIDD/PK-PD modeling, clinical trial design and operations, regulatory affairs, and commercialization/out-licensing support. The company also operates a scalerator model, providing seed capital and growth acceleration to promising biotech startups alongside its consulting and CRO services.
Is 비엑스플랜트 a public or private company?
비엑스플랜트 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 비엑스플랜트 founded?
비엑스플랜트 was founded in 2024. It employs 1 to 10 people.
Where is 비엑스플랜트 based?
비엑스플랜트 is headquartered in Seoul, South Korea, in the Asia region.
How does 비엑스플랜트 make money?
Three revenue lines are on record. CDRO Clinical Development Services are the primary driver. The others are clinical Strategy Consulting and investment / Scalerator Business.
Who are 비엑스플랜트's main competitors?
Broad incumbents on record are IQVIA and Medpace. Direct peers are MediTip, Certara, DreamCIS, LSK Global Pharma Services and C&R Research. Emerging players are Molecular Health, Physiomics and Simulations Plus.
Does 비엑스플랜트 have an API?
No public API is recorded for 비엑스플랜트.
What industry is 비엑스플랜트 in?
비엑스플랜트's product category is Clinical Development Services. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA), with a secondary code of HLAGAEAJ, Companion Diagnostics (CDx) Development & Trial Testing Support. Its NAICS code is 541714 and its SIC code is 8731.